CRISPR/Cas9 gRNA and HR Donor Cloning
Simplify your CRISPR/Cas9 genome engineering—have SBI handle design and cloning of your gRNA and homologous recombination donor constructs
Overview
Jumpstart your genome engineering projects with SBI’s gRNA and HR Donor Cloning Services
While CRISPR/Cas9 technology greatly simplifies genome engineering, successful execution can be surprisingly challenging. An important first step is the careful design and construction of guide RNAs (gRNAs) and homologous recombination (HR) donors. Save yourself time and trouble and have SBI handle this first step (or have SBI complete your entire genome engineering project for you). Our experienced staff understands the intricacies of using Cas9 and has successfully completed dozens of genome engineering projects.
Why choose SBI’s CRISPR/Cas9 genome engineering services?
- Choose either gRNA and HR donor design and construction or our complete Cell Line Engineering Service
- Leverage our well-designed CRISPR/Cas9 products which are used in a number of peer-reviewed papers
- Accomplish more with turn-around times of as little as 1–2 weeks for gRNA cloning, 3–4 weeks for HR donor cloning, and 10–14 weeks for full cell line engineering projects
- Rest easy with your project in the hands of our experienced team that's successfully completed dozens of genome engineering projects
- Enjoy consistent quality, confidentiality, and on-time delivery with all projects completed on-site in our Palo Alto, CA, facility
Not sure what you need or where to begin? Contact the services team to set up a complimentary phone consultation—email services@systembio.com.
Supporting Data
Successful genome engineering with SBI
Successful genome engineering with SBI—effective, efficient knockout of miR-21 in HEK293 cells. gRNA, HR Donor design (with Puro and GFP selection markers), implementation, and analysis performed by SBI’s genome engineering services team. (A) Low relative levels of miR-21—as measured by qPCR in GFP-positive clones—demonstrate the effectiveness of the approach. (B) After excision with Cre recombinase, the inserted GFP and Puro markers are efficiently excised, leaving only a single LoxP site from the HR Donor. From Ho, TT, et al. Targeting noncoding RNAs with the CRISPR/Cas9 system in human cell lines. Nucleic Acids Res. 2015 Feb 18; 43(3):e17. PMCID: PMC4330338.
